Medication info
Olmediquel Tablet 10/40 mg

Olmediquel Tablet 10/40 mg

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›13.888mg / 1 tabletOlmesartan Medoxomil›40mg / 1 tablet
Manufacturer / importer
Handok Co., Ltd.
Appearance
Red-brown round film-coated tablet
Packaging
28 tablets (14 tablets/PTP x 2)
Approval status
Active

MFDS item code 201406181 · Approved 2014.12.31 · Insurance code 652105410

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Administer 1 tablet of this drug once daily with water, regardless of meals. It is recommended, if possible, to take it at the same time each day (e.g., in the morning). Before administering this drug, it is recommended that the dose of the individual component (amlodipine or olmesartan medoxomil) be adjusted. However, if blood pressure is not controlled with monotherapy using an individual component, switching directly to this drug may be considered. The maximum dose of this drug is 10/40 milligrams. Since the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into consideration. The recommended doses are as follows: - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ○ Patients with renal impairment: This drug has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and use of this drug is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients receiving dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients taking diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while monitoring their condition closely. ○ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be monitored closely. This drug should not be administered to patients with severe hepatic impairment. (See section 2, Patients who should not receive this drug, under Precautions for Use.) ○ Elderly patients: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients.
Child dose
○ Children: The safety and efficacy of this drug in pediatric patients under 18 years of age have not been established.

Ingredients

Manufacturer
Handok Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

Amlodipine or Olmesartan Medoxomil is prescribed for patients with essential hypertension who have difficulty controlling blood pressure with monotherapy. These medications effectively lower blood pressure and help reduce the risk of cardiovascular disease. The two drugs stabilize blood pressure through different mechanisms, improving patient health. Managing hypertension plays a crucial role in reducing the likelihood of complications such as heart disease and stroke. Therefore, Amlodipine or Olmesartan Medoxomil is used to treat essential hypertension.

How to take

Adult dose

Administer 1 tablet of this drug once daily with water, regardless of meals. It is recommended, if possible, to take it at the same time each day (e.g., in the morning). Before administering this drug, it is recommended that the dose of the individual component (amlodipine or olmesartan medoxomil) be adjusted. However, if blood pressure is not controlled with monotherapy using an individual component, switching directly to this drug may be considered. The maximum dose of this drug is 10/40 milligrams. Since the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into consideration. The recommended doses are as follows: - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ○ Patients with renal impairment: This drug has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and use of this drug is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients receiving dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients taking diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while monitoring their condition closely. ○ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be monitored closely. This drug should not be administered to patients with severe hepatic impairment. (See section 2, Patients who should not receive this drug, under Precautions for Use.) ○ Elderly patients: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients.

Child dose

○ Children: The safety and efficacy of this drug in pediatric patients under 18 years of age have not been established.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, if pregnancy is confirmed, treatment should be stopped immediately. Patients with allergies to the active ingredients or similar substances, those who are pregnant or breastfeeding, patients with severely impaired liver or kidney function, specific heart valve disease patients, those with bile duct obstruction, patients undergoing kidney dialysis, patients in shock, and specific diabetic patients should not take this medication. In patients who are deficient in fluids or sodium, hypotension may occur, so their condition should be closely monitored during the initial phase of treatment, and appropriate treatment should be provided if hypotension develops. Patients with severe aortic stenosis or obstructive coronary artery disease should be especially cautious, as rapid vasodilation can lead to hypotension. Heart failure patients may experience exacerbation when taking this drug, so dosage and condition should be closely monitored. Patients with impaired kidney function may experience further deterioration of their kidney function, so caution is necessary when taking this medicine, and similar caution is required for patients with reduced liver function. Side effects such as dizziness, headache, hypotension, orthostatic hypotension, edema, dyspepsia, and rash may occur during treatment; patients should consult their doctor if any unusual symptoms appear. During pregnancy, there is a serious risk to the fetus, so this drug should not be used, and if planning for pregnancy, it is recommended to switch to safer alternatives. Breastfeeding mothers should discontinue breastfeeding or stop taking the medicine due to the possibility of the drug being transmitted via breast milk. Children under 18 years of age are advised not to take this medication as safety and efficacy have not been established. Elderly patients may experience an increase in drug concentration due to impaired kidney and liver function; therefore, it is recommended to start with lower doses and take the medication with caution. In cases of overdose, severe hypotension, vasodilation, and tachycardia may occur, necessitating immediate medical attention.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • sensory impairment
  • syncope
Show 80 more
  • vertigo
  • palpitations
  • rapid pulse
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • epigastric pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • back pain
  • polyuria
  • erectile dysfunction
  • peripheral edema
  • edema
  • dependent edema
  • fatigue
  • asthenia
  • facial edema
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyltransferase
  • decreased hemoglobin and hematocrit
  • cholelithiasis
  • female breast neoplasm
  • worsening of cerebral infarction
  • gum bleeding
  • orthostatic dizziness
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • runny nose
  • laryngitis
  • arthritis
  • flank pain
  • generalized pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastroenteritis
  • herpes zoster
  • diplopia
  • asthenia
  • angioedema
  • chronic malabsorption syndrome
  • intestinal vascular edema
  • rhabdomyolysis
  • acute renal failure
  • hair loss
  • itching
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • flushing
  • fatigue
  • edema
  • palpitations
  • vertigo
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • gynecomastia
  • hypotension
  • tachycardia
  • non-cardiogenic pulmonary edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. Additionally, it is best to keep it at a temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Red-brown round film-coated tablet

Package unit

28 tablets (14 tablets/PTP x 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.